At Fox Chase Cancer Center – Temple Health, new leadership within the genitourinary cancer team means innovative new initiatives in groundbreaking research, and patient care is moving forward fast.

Part of this exciting growth at Fox Chase Cancer Center – Temple Health is the appointment of Eric M. Horwitz, MD, FABS, FASTRO, as Chair of the Department of Radiation Oncology at Temple University’s Lewis Katz School of Medicine and the integration of the Department of Radiation Oncology across the health system. In addition to his role as Chair of Fox Chase Cancer Center’s Department of Radiation Oncology, Dr. Horwitz will now oversee a Temple Health system-wide Department of Radiation Oncology.  With this new role comes the responsibility of bringing state-of-the-art radiation cancer care and access to clinical trials to all of the patients within the system.

Since joining the faculty of Fox Chase in 1997, Dr. Horwitz has spearheaded many “firsts” in cancer care. He developed advanced treatment programs for prostate cancer using intensity-modulated radiation therapy, image-guided radiation therapy, and brachytherapy—which led to Fox Chase becoming the first in the northeastern United States to offer HDR implants for prostate cancer and now one of the largest prostate brachytherapy programs in the United States.

In addition, Dr. Horwitz integrated the use of an MRI into the routine use of prostate cancer radiation treatment planning, making Fox Chase Cancer Center the first in the world to do so.

Under Horwitz’s prior leadership, radiation oncology grew exponentially in size and patient volumes. The same can be expected in the years to come.

As a national leader in genitourinary oncology, Elizabeth Plimack, MD, MS, the former chief of the Division of Genitourinary Medical Oncology at Fox Chase Cancer Center, has now been appointed its Deputy Director.

In this newly created role, Plimack will oversee the Clinical and Translational Research Plan—leveraging the vast interdisciplinary clinical and basic science research resources at Fox Chase—to facilitate novel clinical trials to halt cancer.

Another critical new position is the appointment of Daniel M. Geynisman, MD, to Chief, Division of Genitourinary Medical Oncology at Fox Chase Cancer Center. Dr. Geynisman will lead deep collaborations with Urology and Radiation Oncology at Fox Chase—a partnership that benefits prostate, kidney, bladder, penile, adrenal, and testicular cancer patients with its breadth and depth of knowledge.

Dr. Geynisman has co-authored more than 100 manuscripts in peer-reviewed journals and is actively engaged in robust world-class research endeavors, particularly in bladder and kidney cancer.